ALLOAllogene Therapeutics, Inc.
$1.24+2.5% 1Y
$1.24
$1.0552 weeks$3.06
The financials
Allogene Therapeutics, Inc. by the numbers
Allogene Therapeutics, Inc. (ALLO) reported revenue of $4.6M in Q2 2026 (quarter ended Jun 30, 2026), up 480% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $2.6M (+2500% year on year) and net income −$191M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $4.6M | $800K | +480% |
| Operating income | −$47M | −$57M | n/a |
| Net income | −$43M | −$51M | n/a |
| Diluted EPS | −$0.13 | −$0.23 | n/a |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $4.6M
Segment Latestyear on year
- Reportable$4.6M$4.6Myear on year n/an/a